Chenglong Li

Chemistry-Biology Interface Training Program at the University of Florida

AI-directed discovery of heparanase inhibitors

Regulation of enteric norovirus infection by host-derived and microbiota-transformed bile acids

Dual Inhibition of PARP and IL-6 as a Novel Therapeutic Approach for BRCA-Mutated Triple-Negative Breast Cancer

Developing Artificial Intelligence and Machine Learning Approaches to Identify and Optimize Small Molecule Medicines Targeting Oncogenic RNAs

Dual inhibition of PARP and STAT3 as a novel therapeutic approach for triple-negative breast cancer

Mechanisms of Metal Ion Homeostasis of Oral Streptococci

Developing YAP/TEAD Inhibitors for Novel Nash-Associated Hepatocellular Carcinoma Therapeutics

Development of high-affinity and selective ligands as a pharmacological tool for the Dopamine D4 receptor (D4R) subtype variants

Integrative Multidisciplinary Discovery Platform to Unlock Marine Natural Products Therapeutic Opportunities

Computationally designed IL-10 mutants for the treatment of inflammatory bowel diseases

HEC Bench Fee - Tahira Noor

Chemistry-Biology Interface Training Program at the University of Florida

Novel Targeted Anticancer Agents from Marine Cyanobacteria

QLCI-CG: Conceptualization of the Institute for Quantum Biology on Quantum Computers

Mechanistic studies of gamma-glutamyl transpeptidase inhibition: A novel approach to modulating serum levels of cysteine

Role and targeting of PRMT5 in prostate cancer

Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapy

A novel STAT3-selective inhibitor for medulloblastoma therapy

Repositioning Bazedoxifene as a novel IL-6/GP130 inhibitor for sarcoma therapy

Design, Synthesis and Mechanism of ΔF508 Deletion Mutant CFTR Misfolded Small Molecular Corrector

Novel Small Molecules Disabling the IL-6/IL-6R/GP130 Heterohexamer Complex